ReviewEuropean journal of nuclear medicine and molecular imaging2021
Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box.
Review in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Predicting tumour and organ dose in α-radiopharmaceutical therapy: aEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Antibody-Radionuclide Conjugates for Solid Tumors: Multidimensional Strategies from Component Engineering to Synergistic Combination Therapy.International journal of molecular sciences · 2026Review
- Development and Dosimetric Characterization of an In Vitro Benchtop Americium 241 Alpha Irradiator Platform.International journal of radiation oncology, biology, physics · 2026Article
- Targeted alpha therapy: a comprehensive analysis of the biological effects from "local-regional-systemic" dimensions.European journal of nuclear medicine and molecular imaging · 2025Review
- Heterogeneity of absorbed dose distribution in kidney tissues and dose-response modelling of nephrotoxicity in radiopharmaceutical therapy with beta-particle emitters: A review.Zeitschrift fur medizinische Physik · 2024Review
- Advancing the Collaboration Between Imaging and Radiation Oncology.Seminars in radiation oncology · 2024Review
- ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner-Collimator Configurations forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Advances in targeted alpha therapy of cancer.European journal of nuclear medicine and molecular imaging · 2024Article
- Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics.Theranostics · 2024Article
- Efficacy of HER2-Targeted IntraperitonealJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Imaging ofEJNMMI physics · 2023Article
- Optimized SPECT Imaging ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- A machine learning-based model for a dose point kernel calculation.EJNMMI physics · 2023Article
- The United States Department of Energy and National Institutes of Health Collaboration: Medical Care Advances via Discovery in Physical Sciences.Medical physics · 2023Article
- A Machine Learning based model for a Dose Point Kernel calculation.Research square · 2023Article
- Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides.Radiation and environmental biophysics · 2022Review
- Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts.Frontiers in medicine · 2022Review
- Actinium-225 Targeted Agents: Where Are We Now?BrachytherapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiopharmaceutical therapy using α-particle emitting radionuclides (αRPT) is a novel treatment modality that delivers highly potent alpha-particles to cancer cells or their environment. We review the advantages and challenges of imaging and dosimetry in implementing αRPT for cancer patients.
Indexed as
Identifiers
34782911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.